Bio-Connect

Mouse anti Human HLA-DR, conjugated with FITC

Research Use Only
0DR2
Nordic-MUbio
ApplicationsFlow Cytometry
Product group Antibodies
ReactivityHuman
Price on request
100 tests
Large volume orders?
Order with a bulk request

Overview

  • Supplier
    Nordic-MUbio
  • Product Name
    Mouse anti Human HLA-DR, conjugated with FITC
  • Delivery Days Customer
    7
  • Applications
    Flow Cytometry
  • Applications Supplier
    Flow Cytometry
  • Category Supplier
    Primary antibodies
  • Certification
    Research Use Only
  • Clone ID
    423L
  • Concentration
    Titered for flow cytometry
  • Conjugate
    FITC
  • Host
    Mouse
  • Isotype
    IgG2a
  • Scientific Description
    HLA-DR* FITC
  • Shelf life instruction
    See expiration date on vial
  • Source
    Derived from the hybridization of mouse NS-1/1-Ag4 myeloma cells with spleen cells of BALB/c mice immunized with human lymphoblastoid B-cell line RPMI 8866
  • Reactivity
    Human
  • Reactivity Supplier
    Human
  • Storage Instruction
    Product should be stored at 4-8ºC. DO NOT FREEZE
  • UNSPSC
    12352203

References

  • 1. IL-4 and granulocyte-macrophage colony-stimulating factor selectively increase HLA-DR and HLA-DP antigens but not HLA-DQ antigens on human monocytes. Gerrard T.L., Dyer D.R., Mostowski H.S., J. Immunol. 1990 June, 1;144(12): 4670-4. 2. Structural requirements for pairing of alpha and beta chains in HLA-DR and HLA-DP molecules. Karp D.R., Teletski C.L., Jaraquemada D., Maloy W.L., Coligan J.E., Long E.O., J. Exp. Med. 1990 March ;171(3):615-28. 3. Trans-activation of HLA-DR gene by hepatitis B virus X gene product. Hu K.Q., Vierling J.M., Siddiqui A., Proc. Natl. Acad. Sci. USA 1990 SEPT.; 87(18):7140-4. 4. Purified primitive human hematopoietic progenitor cells with long-term in vitro repopulating capacity adhere selectively to irradiated bone marrow stroma. Verfaillie C., Blakolmer K., McGlave P., J. Exp. Med. 1990 Aug.: 172(2):509-2. 5. Defective clonogenic potential of CD8+ T lymphocytes in patients with AIDS. Expansion in vivo of a nonclonogenic CD3+ CD8+ DR+ CD25- T cell population. Pantaleo G., Keonig S., Baseler M., Lane H.C., Fauci A.S., J. Immunol. 1990 Mar ; 144(5):1696-704. 6. Increased circulating HLA-DR+ CD4+ T cells in systemic lupus erythematosus: alterations associated with prednisolone therapy. Raziuddin S., Nur M.A., al-Wabel A.A., Scand. J. Immunol. 1990 Feb.:31(2):139-45.